HeyJaredAPOE4 & Alzheimer’s Prevention | Brain Health Science
A science-driven blueprint for APOE4/4—how I’m actively reducing Alzheimer’s risk, optimizing lipids, and tracking what actually works. Real labs. Real strategies. Real-time learning.
- Indexed issues, last 90 days
- 13
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 9, 2026
Latest issues
A Deeper Dive Into the Results From My RetainMed Visit (opens the original)
Read excerpt
As most of you know, I recently went back for my brain health and APOE4-focused assessments at RetainMed in Boca Raton to meet with specially trained Nurse Practitioners utilizing Dr. Richard Isaacson’s precision prevention methodology, and get my results from the labs taken during my first visit on July 1. Here’s the recap. The photo below was taken after my results were explained and I was preparing to head home! I can't say enough about the RetainMed team—a phenomenal and incredibly knowledge
Obicetrapib: Why There Is So Much Excitement Over The Release Of This Drug. (opens the original)
Read excerpt
If you’ve been following my writing for a while, Obicetrapib is a name you’ve become familiar with.In a previous post, I explained what CETP inhibition is and how it protects the brain and cardiovascular system. The biology is very intriguing - and while the cardiovascular benefits of CETP inhibition have been known for about 30 years - a successful drug development has remained elusive - until now! In addition to astonishing improvements in cardiovascular risk biomarkers, the recent PREVAIL tri
Obicetrapib Just Received European Approval (opens the original)
Read excerpt
Some very exciting news for those of us who have been following obicetrapib, the new oral CETP inhibitor developed by NewAmsterdam Pharma.Today, September 21, 2026, the European Commission granted marketing authorization for obicetrapib, marking its first regulatory approval anywhere in the world.Two versions have been approved:Ubeslo® — obicetrapib 10 mg as a once-daily tablet.Evlarco® — a single tablet combining obicetrapib 10 mg with ezetimibe 10 mg.This is particularly interesting because ob
A New Clue Emerges How APOE4 Damages the Blood-Brain Barrier (opens the original)
Read excerpt
New research identifies fibronectin as a potential link between APOE4, inflammation and blood-brain barrier dysfunction—and points toward some intriguing possibilities for prevention research.In the years I’ve been researching the APOE4 and AD Prevention topic, I’ve often seen reference to the integrity of our blood-brain barrier (BBB). The BBB is a highly specialized vascular system that controls what passes from our circulation into the brain - both the good and the bad.We have known for some
Interesting New APOE4 Research Which Takes Me Back to Dr. Alan Green and Rapamycin (opens the original)
Read excerpt
Some fascinating new research out of Stockholm University is looking at something we don’t normally associate with Alzheimer’s disease: the liver.The researchers are investigating whether APOE4 produced in the liver may contribute to Alzheimer’s risk through its effects on metabolism, inflammation and the vascular system - even though liver-produced APOE itself does not cross the blood-brain barrier (BBB).Why did this immediately catch my attention?Because it bro
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about APOE4 & Alzheimer’s Prevention | Brain Health Science